Medicare AdvantagePrior AuthLow impact
Alternate nilotinib products (Danziten, nilotinib tartrate-Cipla) (Revised)
Humana·Hematology, Oncology·Medicare Advantage
Effective date
Feb 26, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for alternate nilotinib products (Danziten tablets and nilotinib tartrate-Cipla capsules) used to treat chronic myeloid leukemia. Patients must be 18+ with CML diagnosis and cannot have experienced disease progression on any nilotinib product.
Action Required
By February 26, 2025: Billing team must obtain prior authorization from Humana Medicare Advantage before prescribing Danziten tablets or nilotinib tartrate-Cipla capsules for CML patients. Verify patient is 18+, has CML diagnosis, and has not experienced disease progression on any nilotinib product. Visit www.humana.com/PAL for medical coding information and prior authorization requests.